A CRISPR-based topical therapy halts damaging blood vessel growth in the eye
A recent study in *Gene Therapy* demonstrates a novel application of CRISPR-Cas9 gene-editing technology for a condition with significant parallels to inflammatory arthritis complications. Researchers successfully used a topical application of Cas9 ribonucleoproteins to inhibit corneal neovascularization—the abnormal growth of blood vessels in the cornea—in a mouse model of alkali burn injury. This approach directly targets the genetic drivers of pathological angiogenesis, a process central to conditions like rheumatoid arthritis where synovial inflammation and pannus formation rely on new blood vessels. The study highlights a shift towards localized, precision genetic interventions that could circumvent the systemic side effects associated with current biologic therapies and DMARDs.
Study Significance: For rheumatology, this research is methodologically adjacent but conceptually significant, offering a potential blueprint for targeting localized inflammatory processes like synovitis or enthesitis. The success of a topical, non-invasive delivery system for a powerful gene-editing tool suggests future pathways for treating refractory joint-specific inflammation in diseases like psoriatic arthritis or ankylosing spondylitis, potentially preserving cartilage and preventing joint erosion. It prompts strategic consideration of how next-generation therapies might move beyond systemic immunosuppression to achieve site-specific disease modification with fewer off-target effects.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
